MOD-15014
/ OPKO Health
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 18, 2021
Opko Health (OPK) Q4 2020 Earnings Call Transcript
(The Motley Fool)
- "Our GLP-2 molecule for the treatment of short bowel syndrome is expected to enter clinical trials in late 2021."
New trial • Short Bowel Syndrome
1 to 1
Of
1
Go to page
1